Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Although cardiac involvement is relatively common in mixed connective tissue disease (MCTD), few reports on MCTD-associated fulminant myocarditis are available.
Case Summary: A 22-year-old woman diagnosed with MCTD was admitted to our institution for cold-like symptoms and chest pain. Echocardiography revealed that the left ventricular ejection fraction (LVEF) had rapidly decreased from 50 to 20%. Because endomyocardial biopsy revealed no significant lymphocytic infiltration, immunosuppressant drugs were not started initially; however, steroid pulse therapy (methylprednisolone, one1000 mg/day) was initiated due to prolonged symptoms and unimproved haemodynamics. Despite strong immunosuppressant therapy, the LVEF did not improve, and severe mitral regurgitation appeared. Three days after steroid pulse therapy initiation, she experienced a sudden cardiac arrest; thus, venoarterial extracorporeal membrane oxygenation (VA-ECMO) and intra-aortic balloon pumping (IABP) were initiated. Subsequent immunosuppressant therapy was continued with prednisolone (100 mg/day) and intravenous cyclophosphamide (1000 mg). Six days after steroid therapy initiation, the LVEF improved to 40% and then recovered to near-normal levels. After successful weaning off of VA-ECMO and IABP, she was discharged. Thereafter, a detailed histopathological examination revealed multi-focal signs of ischaemic micro-circulatory injury and diffuse HLA-DR in the vascular endothelium, suggesting an autoimmune inflammatory response.
Discussion: We report a rare case of fulminant myocarditis in a patient with MCTD who recovered with immunosuppressive treatment. Despite the absence of significant lymphocytic infiltration findings on histopathological examination, patients with MCTD may experience a dramatic clinical course. Although it is unclear whether myocarditis is triggered by viral infections, certain autoimmune mechanisms may lead to its development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122413 | PMC |
| http://dx.doi.org/10.1093/ehjcr/ytad174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fulminant Influenza A Myocarditis in a Healthy Young Adult Salvaged With Biventricular Impella Support: A Case Report.
Cureus
August 2025
Internal Medicine, Baptist Memorial Hospital-North Mississippi, Oxford, USA.
Fulminant myocarditis is a rare but life-threatening complication of influenza A infection that can result in acute biventricular failure leading to cardiogenic shock. Here, we present the case of a young patient who developed acute bilateral heart failure secondary to influenza A and was successfully stabilized using both right and left-sided Impella devices. This case highlights the critical role of early and aggressive mechanical circulatory support (MCS) in managing fulminant myocarditis and emphasizes the utility of Impella in cases of severe cardiac dysfunction.
View Article and Find Full Text PDFFulminant Viral Myocarditis Associated with Thogotovirus.
N Engl J Med
September 2025
Chiba University, Chiba, Japan.
A case report of fulminant eosinophilic myo-pericarditis related to checkpoint inhibitors complicated by acute heart failure and cardiac tamponade.
Eur Heart J Case Rep
August 2025
Division of Cardiovascular Medicine, University of Virginia, PO Box 8000662, Charlottesville, VA 22908, USA.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with various adverse effects, including myocarditis, with mortality rates up to 50%. We report a case of fatal ICI-related fulminant eosinophilic myo-pericarditis complicated by tamponade in a 69-year-old man with metastatic lung adenocarcinoma.
Case Summary: Two weeks after receiving one dose of pembrolizumab, the patient presented with sudden chest pain and dyspnoea.
Fulminant Myocarditis After mRNA COVID-19 Vaccine Evolving to Giant Cell Myocarditis.
JACC Case Rep
August 2025
Department of Medicine, Division of Cardiology, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada. Electronic address:
Background: Pediatric inflammatory multisystem syndrome (PIMS-TS) is a rare entity observed in children with postinfectious hyperinflammatory syndrome. Cases have been reported, although rarely, after the mRNA SARS-CoV-2 (COVID-19) vaccine.
Case Summary: We present a case of a young man who developed PIMS-TS with fulminant myocarditis after a first dose of COVID-19 vaccination, with persistent evidence of inflammation despite multiple lines of therapy over the course of 2 years.
Beyond the lungs: a case report of disseminated cutaneous aspergillosis highlighting clinical dilemmas in invasive fungal infections of critically ill patients.
J Mycol Med
August 2025
Department of Intensive Care Unit, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China. Electronic address:
With opportunistic fungal pathogens increasingly recognized as a global public health threat, the population at high risk for invasive fungal infections (IFIs) has expanded beyond traditionally immunocompromised individuals-such as those with malignancies, organ transplantation, diabetes mellitus, or acquired immunodeficiency syndrome (AIDS)-to include critically ill patients in intensive care units (ICUs) receiving invasive support and immunomodulatory therapies. Invasive aspergillosis (IA) is one of the most lethal opportunistic infections in this population, characterized by insidious onset, clinical heterogeneity, and a lack of specific signs, often resulting in delayed diagnosis. Disseminated or breakthrough aspergillosis carries an exceedingly high mortality rate.
View Article and Find Full Text PDF